Drugs / Para-aminohippurate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT04649229 Background | May 2021 → May 2025 | heart failure | Yale University | Completed | No outcome recorded |
| — | NCT00431665 Background | Jul 1999 → Jun 2000 | — | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | paraamino hippurate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00431665 ↗ |
| Known as | PAH | “Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.” NCT04649229 ↗1“paraamino hippurate (PAH)” NCT00431665 ↗ |